Get the Stockscreener App
1.2813
2.93%
-0.0387
Aspire Biopharma Holdings Inc stock is traded at $1.2813, with a volume of 111.62K.
It is down -2.93% in the last 24 hours and down -2.93% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$1.32
Open:
$1.3
24h Volume:
111.62K
Relative Volume:
0.12
Market Cap:
$6.44M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-0.7625
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
-11.63%
1M Performance:
-2.93%
6M Performance:
-93.74%
1Y Performance:
-95.84%
1-Day Range:
$1.2408
$1.34
1-Week Range:
$1.2408
$1.5918
52-Week Range:
$1.20
$36.48
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.2813 | 6.63M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
ASBP SEC FilingsAspire Biopharma Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ASBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - The Sheboygan Press
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Bergen Record
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief - ACCESS Newswire
New under-the-tongue alprazolam powder aims to calm anxiety faster - Stock Titan
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Oak Ridger
Aspire Biopharma Provides Q3 2025 Business Update - Las Cruces Sun-News
Aspire Biopharma Announces Reverse Stock Split - Daily American
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - The Chronicle-Journal
ASBP Technical Analysis & Stock Price Forecast - Intellectia AI
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - Victorville Daily Press
ASBP Technical Analysis & ETF Price Forecast - Intellectia AI
ASBP Should I Buy - Intellectia AI
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship - Digital Journal
Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Buzz Bomb Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship - FinanzNachrichten.de
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign - Pocono Record
Aspire Biopharma (ASBP) seeks reverse split, $100M equity line and share increase - Stock Titan
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):